Clinical trial
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in…
NCT00191789 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191789 |
|---|---|
| Title | Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer |
| Official title | Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gemcitabine, doxorubicin, cisplatin, surgery |
| Enrollment | 65 |
| Start date | Feb 1, 2003 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 27, 2010 |
| Countries | India |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: